Tobacco-specific nitrosamine adducts: studies in laboratory animals and humans. by Hecht, S S et al.
Environmental Health Perspectives
Vol. 99, pp. 57-63, 1993
Tobacco-Specific Nitrosamine Adducts:
Studies in Laboratory Animals and
Humans
by Stephen S. Hecht,' Steven G. Carmella,' Peter G.
Foiles,' Sharon E. Murphy,' and Lisa A. Peterson'
This paper describes quantitation of human hemoglobin and DNA adducts of the carcinogenic tobacco-specific
nitrosamines4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) andN'-nitrosonornicotine (NNN). NNKand NNN
arebelieved tobeinvolvedin cancersofthelung,esophagus, onlcavity, and pancreasinpeoplewho usetobaccoproducts.
Theadductdosimetry methodemploysGC-MSforquantitation of4-hydroxy-1-(3-pyridyl)-1-butanone (HPB) released
by mild base hydrolysis ofhemoglobin or acidhydrolysis ofDNA as a biochemical marker ofthe pyridyloxobutylation
metabolic activation pathway. Approximately 22% of smokers (n = 101) had elevated levels of HPB released from
hemoglobin(range, 200-1600fmole/gHb). Adductlevelsinsnuffdippersrangedfrom2001800fmole/gHb. HPBlevels
in nonsmokers weregenerally below the detection limit. Acidhydrolysis oflungand tracheal DNA obtained at autopsy
andanalysis for released HPB revealed levelsranging up to50fmole/mgDNA in smokers; the adduct was not detected
in nonsmokers. These findings are consistent with data generated in studies ofadduct formation by NNK in rats. The
biological significance oftheHPB-releasingDNA pyridylksobutylation pathway wascomparedtothatoftheDNAmethyla-
tionpathway intheA/J mouse. Thesestudiesdemonstratedthatthe persistenceof O'-methylguanine inlungDNA iscritical
fortumorigenesisbyNNKandthatpyridylaobutylationenhancesboth peristenceofO-methylguanineandtumorigenesis
by acetoxymethylmethylnitrosamine. In the rat, the relative roles of methylation and pyridyloxobutylation in lung
tumorigenesis by NNK are not as clearly defined. Although the biological significance of DNA methylation in NNK
tumorigenesis iswell characterized, dosimetry studiesoftobacco-specific nitrosamines inhumans should be carried out
using biochemical markers ofthe pyridyloxobutylation pathway because oftheir specificity totobacco products.
Introduction
Smoking is a well-established cause of cancer of the lung,
larynx, oral cavity, esophagus, pancreas, andbladder (1). Oral
useofsmokeless tobacco causes oral cavity cancer(2). Tobac-
co users experience an intense and prolonged exposure to car-
cinogens and are therefore an appropriate group in which to
assess carcinogen dosimetry. Among the various carcinogens
present in tobacco smoke, three groups ofcompounds, poly-
nuclear aromatic hydrocarbons, aromatic amines, and
nitrosamines, appear to play major roles as causes of human
cancers (3). Of the compounds present in unburned tobacco,
nitrosamines are the most likely causes of cancer (3,4). Other
papers inthis issue describedosimetry studies thathaveassessed
polynuclear aromatic hydrocarbon and aromatic amine adduct
levels in individuals exposed totobaccosmoke. Inthis paper, we
focus on adducts of two tobacco-specific nitrosamines, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and
N'-nitrosonornicotine (NNN). NNK and NNN have been im-
plicated as causes ofcancers ofthe lung, esophagus, oral cavi-
ty, and pancreas in tobacco users (3,4). This is based on their
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relatively high levels in tobacco products and on bioassays in
laboratory animalsthatclearlydemonstratetheirtumorigenicac-
tivities inthesetissues. Wehavedeveloped methods to measure
hemoglobinandDNAadductsofNNKandNNNinhumans. We
discussthesestudiesanddescribeparallelresearchinlaboratory
animals designed to increase our understanding of the meas-
urements being made in humans.
Adduct Formation by NNK and NNN
Figure 1 showsthemetabolicpathwaysthatareknowntoform
hemoglobin and DNA adducts of NNK and NNN. The me-
tabolism ofthese compounds has been extensively studied in
laboratoryanimals(5-11). Hydroxylationofthecarbonsadjacent
to the nitroso nitrogen (c-hydroxylation) is the majorpathway
producingadducts. NNKishydroxylatedbycytochrome P-450
isozymes, and possibly by other mechanisms, to produce in-
termediates (1 and 2 in Fig. 1) (11). These intermediates are
unstableandspontaneously decompose toeitherketoaldehyde
(4 in Fig. 1) and methanediazohydroxide (5 in Fig. 1) or to for-
maldehyde (6 in Fig. 1) and 4-(3-pyridyl)-4-oxobutanediazo-
hydroxide (7 in Fig. 1).
Methanediazohydroxide methylates globin to produce un-
knownadducts and methylates DNA, giving7-methylguanine,N=O 0 l
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FIGURE 1. Metabolic activation ofNNK and NNN tointermediates thatbind to hemoglobin and DNA.
06-methylguanine, and 04-methylthymidine. Other DNA ad-
ducts areprobably formed, butthey havenotbeenidentified in
NNK-treatedanimals. Diazohydroxide (7 inFig. 1) reacts with
globin to produce a carboxylic ester adduct, which is readily
hydrolyzed with base, yielding 4-hydroxy-1-(3-pyridyl)-1-but-
anone (HPB). Reaction of diazohydride with DNA, possibly
through acyclic oxonium intermediate (12), givesanadductof
unknown structure that is hydrolyzed to HPB with acid.
AlthoughotherpathwaysofNNKmetabolism suchaspyridine-
N-oxidation, pyridine ring oxidation, and carbonyl reduction
havebeen well characterized, thepathways illustrated inFigure
1 appeartobethemajorreactions leading toadductformation.
ca-Hydroxylation of NNN at the carbon adjacent to the
pyridine ring produces 2'-hydroxyNNN (3 in Fig. 1), which
spontaneously decomposes to diazohydroxide (7 in Fig. 1),
resulting informationofthe sameglobinand DNAadductsthat
areproducedbymethylhydroxylationofNNK. Asinthecaseof
NNK, Figure 1 isanoversimplification. AllcarbonsoftheNNN
pyrrolidine ring are hydroxylated, and the pyridine nitrogen is
oxidized. Noneofthesepathwayshaveyetbeenassociated with
adduct formation.
These metabolism studies in laboratory animals established
thebasicpatternsofNNKandNNNmetabolismandadductfor-
mation. ThereleaseofHPBfromeitherglobinorDNAbymild
hydrolysis was especially attractive to us for use in dosimetry
studies forseveral reasons. First, HPBcouldbereadilyseparated
from otherconstituents ofglobin orDNAby simpleextraction.
Second, HPBcaneasilybederivatizedtoimproveitsdetectabili-
ty. Third, HPBis structurally derivedfromNNKandNNNvia
diazohydroxide (7 in Fig. 1). Therefore, HPB shouldprovide a
specific markerformetabolicactivationofNNKandNNN. This
is not the case for DNA methylation by NNK since there are
many other sources ofhuman exposure to methylating agents.
Analysis of Hydrolysates of Human
Hemoglobin or DNA for HPB
The analytical sensitivity required for the analysis of hy-
drolysates is in the parts per trillion range. This sensitivity is
achievedbyderivatizationofHPBas itspentafluorobenzoate and
quantitation by negative ion chemical ionization mass spec-
trometry. ThedetectionlimitforHPB-pentafluorobenzoate isap-
proximately 100amole. Specificity isachievedbythecombina-
tion ofcapillary column gas chromatography and selected ion
monitoring. Quantitationisaccomplishedusingd2-HPBasan in-
ternal standard, and HPB-tetrafluorobenzoate as an external
standard. Methods for the analysis ofHPB released from base
hydrolysates of human hemoglobin or acid hydrolysates of
humanDNAhavebeenpublished (13,14). Figure2summarizes
the analytical scheme used for analysis ofHPB released from
hemoglobin; the methodforDNA is similarexceptthatthe in-
itial step is acidhydrolysis. Validation studies have shown that
both methods arepreciseand reliable (13,14).
Figure 3 presents dataobtained in ongoing analyses ofHPB
released fromhumanhemoglobin. Thesamples wereobtained
from smokers, snuff dippers, and nonsmokers. Figure 3 il-
lustratesseveralnoteworthypoints. First, HPBlevelsinsmokers
andsnuffdippersarehigherthaninnonsmokers. Thisisconsis-
tentwiththefactthatNNKandNNNarederivedfromnicotine
and are therefore associated only with nicotine-containing
productssuchastobaccoandtobaccosmoke. Themeanlevelof
HPB-releasinghemoglobinadductsinnonsmokersislowerthan
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FIGURE 2. Scheme for the analysis of 4-hydroxy-1-(3-pyridyl)-1-butanone
released from human hemoglobin.
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FIGURE 3. Levels of 4-hydroxy-1-(3-pyridyl)-1-butanone released from
hemoglobin adducts ofnonsmokers, smokers, and snuffdippers.
that of almost any other hemoglobin adduct that has been
measured (13). Someofthelowernonsmokervaluesillustrated
in Figure 1 may be due to methodological background. The
comparisons between nonsmokers and tobacco users indicate
that detection of HPB in hydrolysates of human hemoglobin
shouldprovideareliablemarkerforchronic exposuretotobac-
co products. This may beimportant for studies ofthe relation-
ship ofenvironmental tobacco smoke to cancer.
Second, thereisawidespreadintheHPBlevelsmeasured in
bothsmokersandsnuffdippers, rangingfromnotdetectedtoap-
proximately 1800 fmole/g Hb. This is consistent with in vitro
studies incultured humantissues, whichhaveindicated thatin-
dividuals differ intheir capacity tometabolically activate NNK
and NNN by the pathways illustrated in Figure 1 (15).
Several factors other than metabolic activation could con-
tributetohighlevelsoftheHPB-releasing adducts. Thedoseof
NNK and NNNwillbeaffectedbyanindividual's smoking pat-
tern or the extent of one's smokeless tobacco use. The ni-
trosamines may alsobeformedendogenously from nicotine or
nornicotine. ThepersistenceoftheHPB-releasinghemoglobin
adduct in humans is not well understood at present, although,
based on studies in rats, the adduct appears to have a shorter
lifetime thantheerythrocyte. Thesefactors requirefurtherstudy.
Ourhypothesis is thathigherhemoglobin adduct levels will be
associated with higher DNA adduct levels and consequently
higher cancer risk. This is being tested in ongoing studies.
Third, only about 20% of smokers have HPB-releasing
hemoglobinadduct levelsthatarehigherthanthose incontrols.
Thismay relatetosomeofthefactorsdiscussedabove. Itwillbe
importanttodeterminewhatcontributestothesehighlevelsand
their relationship to risk.
Fourth, snuffdippers havehigherHPB-releasing hemoglobin
adduct levels than smokers, at least among the individuals ex-
amined to date. Thereasons forthis arecurrently unknownbut
couldrelate todifferences inenzymeinductionpatternsbetween
snuff dippers and smokers. Perhaps constituents of tobacco
smokethatare notpresentinsnuffcaninducethedetoxification
ofNNK and NNN. Nevertheless, theresults with snuffdippers
supportourhypothesis thatNNKandNNNareinvolved inoral
cancer induction because they show that snuff dippers can
metabolically activatethesecarcinogens. NNKandNNN areby
farthe mostabundant strongcarcinogens insnuff, andthey are
theonly carcinogens thathavebeen showntoinduceoraltumors
in rats (4,16).
Further insight on thevalues in Figure 3 can beobtained by
comparing the HPBvalues tothoseobtaineduponchronic treat-
ment of rats with NNK. Rats treated five times weekly for 5
weeksby IPinjection of0.5, 1, or5 jg/kgNNKhad247 + 5.9,
517 + 3.2, or 1916 + 153 fmole/g HbofHPB-releasing adducts
intheirhemoglobin. These results suggestthattheeffective ex-
posure ofsnuffdippers todiazohydroxide (7 in Fig. 1) was be-
tween 0.5 and 1 pg/kg/day. This is higher than the exposure
calculated fromlevelsofNNKand NNN insnuff, which would
amount to approximately 0.1 pg/kg/day (13). Similarly, the
results suggestasomewhathigher meanexposureofsmokersto
diazohydroxide (7inFig. 1)thanwouldhavebeenexpectedbased
only on calculations using levels of NNK and NNN in
mainstream smoke (13). Overall, thelevelsofHPB-releasing ad-
ducts measured inhumans wereintherangeexpectedbased on
themeasurements madeinratstreatedwithNNK. Thissupports
the concept thatthe adductsbeing determined in humans do in
fact result from exposure to NNK andNNN.
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FIGURE 4. Levels of4-hydroxy-1-(3-pyridyl)-1-butanone released from DNA
adducts inperipheral lungandtracheobronchusofnonsmokersandsmokers.
Figure 4 summarizes data obtained from analysis ofhuman
peripheral lungandtracheobronchusforlevelsofHPBreleased
from DNA (14). The samples wereobtained atimmediateautop-
sy. The datashow that HPB levels werehigher insmokers than
in nonsmokers, which is consistent with the hemoglobin
analyses. The mean levelofHPB released fromperipheral lung
DNAofsmokers was 11,000fmole/gDNA(0.0164tmole/Amole
deoxyguanosine), about 70 times higher than the mean level
released fromglobinofsmokers (163 fmole/g Hb). Inrats, atthe
lowest dose ofNNK examined, HPB released fromlung DNA
was about 20 times greater than from hemoglobin when
expressedpergramofmacromolecule(17). Thesestudies, taken
together withthosedescribed above, showgoodagreementbe-
tween the results in rats and humans.
When NNK was given in the drinking water to rats at a dose
of0.5 ppm forlife, asignificant incidenceoflungandpancreatic
tumors was induced whenmeasured aspartofadose-response
study (18). We estimate thatthe levelsofHPB-releasing hemo-
globinadducts inthese ratswouldbeabout8000fmole/gHb, or
about 50 times higher than the mean level seen in smokers.
Relationship between Hemoglobin Ad-
ductsand DNAAdductsofNNKin Rats
Withcurrenfly availablemethodology, it is morepractical to
quantify hemoglobin adducts than DNA adducts. In these
studies, we wish to use HPB released from hemoglobin to
estimate levels ofHPB-releasing adducts in targettissue DNA
andpossibly to establisha relationship between levels ofHPB-
releasing adducts and levels of DNA methylation. These are
complex issueswhich wouldbestbeaddressedby quantifyingall
of these adduct levels in the same individuals. Approaches
toward this goal are being developed. However, we have com-
pared levelsofpyridyloxobutylation and methylation in hemo-
globin and DNA ofrats treated with NNK.
Rats were treated with four IP doses of various amounts of
NNK, labeledeitherinthemethylgrouporthepyridinering, and
sacrificed4hrafterthelastinjection (17). FigureS illustratesthe
levelsoftotaltritiumboundtoglobinandofHPBreleased. There
wasalinearrelationshipbetweendoseandtritiuminglobinover
fourordersofmagnitude. The structures ofthe methyl adducts
are notknown, butthey are notesters. Dependingon dose, the
adductthatreleases HPBuponhydrolysisaccounted for 17-40%
oftheboundtritium. Thisadducthasbeenidentifiedasacarbox-
ylic ester (19).
The relationships between DNA andglobinpyridyloxobutyla-
tion and methylation are summarized in Figures 6 and 7.
Whereas globin alkylationby both pathways increasedlinearly,
levels of HPB released from lung or liver DNA and levels of
7-methylguanine in lung and liver DNA did not increase in a
linear fashion. In lung, both pathways ofDNA alkylation were
moreprevalentatlowerdosesthanwouldhavebeenexpectedby
extrapolationfromhigherdoses. Thishasalsobeenobserved for
06-methylguanine inratlungandClaracell DNAandmay relate
to the presence ofahigh-affinity cytochrome P-450 form or to
otherfactors(20). Theratioof7-methylguanine toHPB released
fromlung DNAdecreased withdose; itwas7.5 afterfourdoses
of15Ag/kg/dayofNNK. This suggeststhatthesepathways may
bequantitatively similaratthedosesofNNKtowhichsmokers
are exposed.
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FIGURE 5. Log-logplotofthelevelsoftritium in ratglobinafterfourdaily IP
injections (3-10,000 Ag/kg) of either [C3H3]NNK or [5-3H]NNK, and
4-hydroxy-1-(3-pyridyl)-1-butanone released from globinofthe latter.
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FIGURE 7. Log-log plot oflevels of7-methylguanine in lungand liver DNA
and total tritium inglobin after treatment ofrats with [C3H3]NNK (3-10,000
,ug/kg/day for 4 days).
Although levels ofDNA adducts and hemoglobin adducts in-
crease with dose, the nonlinear relationship between DNA al-
kylation anddose suggests thatestimation ofDNA adduct levels
from hemoglobin adduct levels may be complex. There are
severalproblemsthatneedtobeaddressedbeforethiscanbecon-
fidently attempted. The mechanism ofhemoglobin adduct for-
mation is unclear. Presumably, thediazohydroxide is formed in
metabolizingcells oftheliverorperhaps lung andmigrates in-
totheerythrocytewhere itreacts withglobin. However, fewdata
are available. IfdifferentcytochromeP-450 isozymes carry out
methylene ormethyl hydroxylation indifferenttissues, as seems
likely, theircontributionstoglobinadductformationcouldvary
widely. ThecontributionofDNArepair, which isknowntooc-
cur for 06-methylguanine, is another complication. Further
studies assessing DNAandhemoglobinadductlevels inhumans
are required to resolve some ofthese issues.
Roles of DNA Methylation and
Pyridyloxobutylation in Lung Tumor
Induction by NNK
InA/J mice, NNK is aneffectivepulmonary carcinogen. We
havedeveloped a single-dose model for NNK tumorigenesis in
themouselung, inwhich 10Amole NNKgiven IPinduces 8-10
lung tumors per mouse 16 weeks after injection (21). We have
usedthis model to investigate theimportance ofDNA methyla-
tion and pyridyloxobutylation in mouse lung tumorigenesis.
Substitution of deuteriums at the methylene carbon of NNK
decreased levels of06-methylguanineinlung DNAanddecreas-
ed tumorigenicity compared to NNK, whereas substitution of
deuteriums atthemethylcarbonhadnomajoreffect(22). These
studies indicated that methylation was more important than
pyridyloxobutylation inthe inductionofmouse lung tumors by
NNK. This was consistent withtheobservationofBelinsky and
co-workers (23) thatahighpercentageofmouselungtumors in-
ducedby NNK hadaG-Cmutation inthe secondbaseofcodon
12 ofthe K-ms gene, presumably as aresultoftheformation of
06-methylguanine at this position.
Toinvestigate therolesofmethylation andpyridyloxobutyla-
tion morethoroughly, wehavecomparedthe DNAbinding and
tumorigenicity ofacetoxymethylmethylnitrosamine (AMMN),
apuremethylating agent, and4-(acetoxymethylnitrosamino)-l-
(3-pyridyl)-l-butanone (NNKOAc), apurepyridyloxobutylating
agent(24). DNAbindingstudies werecarried outtodetermine
dosesofthesecompounds thatwouldproducethesamelevels of
methylated and pyridyloxobutylated DNA as did NNK. Then,
the tumorigenic activities ofthese doses were determined.The
results showed that AMMN was more tumorigenic than
NNKOAc in mouse lung. Doses ofAMMN that gave the same
levels ofpersistent O6-methylguaninein DNA as NNK had the
sametumorigenicity as NNK. Interestingly, NNKOAc increased
both the initial levels and persistence of 06-methylguanine
inducedbyAMMN, andcombinationsofanontumorigenic dose
ofNNKOAcandAMMNweremoretumorigenic than AMMN
alone over a range of doses, as illustrated in Figure 8. Thus,
pyridyloxobutylation appears tobeacocarcinogenformethyla-
tion, presumably byaffectingtherepairof06-methylguanine in
mouse lung.
A striking correlation was observed between levels of 06_
methylguanine in mouse lung 96 hr after injection and the
tumorigenic activities of AMMN, AMMN + NNKOAc, or
NNK(Fig. 9). Theseresults indicatethat06-methylguanine for-
mationisacriticaldeterminantofmouselungtumorigenesis in-
duced by NNK.
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FIGURE 9. Relationship between tumor incidence and concentration of06-
methylguanine(06-MeG) inlung DNA96hraftertreatmentwith NNK(0),
acetoxymethylmethylnitrosamine (A), oracetoxymethylmethylnitrosamine
+ 4.2 Amole 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-l-butanone (-).
IntheF344rat, lungtumorsareinducedbychronictreatment
with NNK, given either by SC injection or in drinking water
(6,18). Deuterium substitution studies analogous to those de-
scribed above were inconclusive (25). Neither substitution of
deuterium atthemethylene normethylcarbonhadanyeffecton
tumorigenicity. Nevertheless, a dose-response study of 06_
methylguanine levels in Clara cell DNA and lung tumor in-
cidence in ratstreatedwithNNKshowedastrongcorrelationbe-
tweenthesetwoparameters, similartothatillustratedinFigure
9(20). Theseresults indicatedanimportantrolefor06-methyl-
guanine in lung tumorinductionby NNK intherat. Ifthis were
the case, perhaps thecarcinogenicity ofmethylenedeuterated-
NNK should have been less than that of NNK; this was not
observed. A further complication is that the tumors appear to
arisefromthealveolartypeIIcellsofthelung intherat, andno
correlation between 06-methylguanine and tumorigenicity was
observed in these cells (20). In contrast to the A/J mouse, ac-
tivated oncogenes have notbeen identified inthelungs ofF344
ratstreated with NNK (26). Thus, therelativerolesofmethyla-
tion andpyridyloxobutylation intheinductionoftumors inthe
ratlung are notclearatpresent, althoughitappearsthatmethyla-
tion is important in some way.
Theuncertain role ofpyridyloxobutylation in tumorigenesis
ispartlyduetothepresentlackofstructural dataontheDNAad-
ducts. Although these adducts are relatively stable in double-
stranded DNAin vitroandin vivo, themajoronesareapparently
unstable atthenucleoside level, spontaneously producing HPB
(27). This requires furtherinvestigation. Nevertheless, several
lines ofevidence supporttheconceptthatpyridyloxobutylation
plays a role in tumorigenesis. First, NNN, which does not
methylate DNA, is still aneffectivecarcinogen, inducing tumors
oftheesophagus andnasalcavity inrats (6). Second, NNKOAc
andarelatedmodelcompoundthatgeneratediazohydroxide (7
inFig. 1)uponhydrolysisarehighlymutagenicinS. typhimurium
strains, showing greateractivity thanAMMN. Consistentwith
this, methyl deuterated-NNK was not mutagenic, but both
methylene deuterated-NNK as well as NNK alone were
mutagenic towardS. typhimurium inthepresenceofanactivating
system (28). Third, studiesofmutations inducedbymetabolical-
ly activated NNKintheE. colilacIgene indicatethepresence
ofacomplexmutational spectrumconsistentwithbothmethyla-
tion and pyridyloxobutylation ofDNA (29).
Although the role ofDNA methylation in tumorigenesis by
NNKismoreclearlydefinedthanthatofpyridyloxobutylation,
we believe that dosimetry studies of NNK should use bio-
chemical markers that are specifically related to its structure,
ratherthanthoserelatedtomethylation. Sourcesofmethylating
agents such asdimethylnitrosamine areubiquitous, and conse-
quently methyl adductsaredifficulttospecifically tracetotobac-
coproducts.
Conclusions
We have developed methods to quantify HPB released upon
mildacidorbasehydrolysisofhumanDNAorhemoglobin. The
HPB-releasingadductsareformeduponmetabolicactivationof
thecarcinogenic tobacco-specificnitrosamines NNKandNNN.
Althoughtherelationshipofadductlevelstoanindividual'srisk
for developing tobacco-related cancers is not yet known, it is
clear that certain individuals who use tobacco products have
relativelyhighlevelsoftheseadductscomparedtononsmokers.
Thepresentmethodology will contribute to ourunderstanding
ofthe metabolic activation ofNNK and NNN in humans.
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